With the wave of innovation in the pharmaceutical industry, many enterprises are accelerating projects such as building new R&D production bases in order to improve profitability, enhance innovative R&D capabilities, supplement product lines, and improve industrial layout
.
In the past month, a large number of pharmaceutical companies have announced that they will invest heavily in new innovation, production, service platforms and other projects
.
For example, on December 13, Bluesail Medical announced that the company intends to invest in the construction of Lanfan Medical Science and Technology Innovation Headquarters and Industrialization Base Project in Shanghai International Medical Park, Pudong New Area, Shanghai, for the global commercial headquarters of Lanfan Medical and the production base of high-value medical devices, and will undertake the R&D and production functions of 5 product lines of Lanfan Medical coronary intervention, structural heart disease, peripheral intervention, neurointerventional and minimally invasive surgery in the future, as well as the headquarters functions of Lanfan Medical's high-end medical devices, including but not limited to strategic planning, investment and mergers and acquisitions, financial centers, etc
.
The total investment amount of the project is about 2.
48 billion yuan, of which the proposed investment amount of the first phase project is 770 million yuan and the second phase project is 1.
71 billion yuan
.
The total investment of the final project is subject to the actual investment, and the investment
will be made as needed according to the actual progress of the project.
On November 28, Yiqiao Shenzhou issued an announcement that the company intends to sign the "Entering the Zone Agreement" with the Beijing Economic and Technological Development Zone Management Committee, purchase land use rights and house ownership according to the agreement, the company will build Yiqiao Shenzhou Biomedical Innovation Public Service Platform and Achievement Transformation Base Project in the Development Zone, the total investment amount of the project is not less than 1 billion yuan, the main construction content of the project is to build a one-stop biological reagent and technical service platform, build a biomedical innovation service-oriented comprehensive park, and the project will reach production within two years from the date of production Production is expected to reach in 2025
.
According to public information, Yiqiao Shenzhou, listed on the Growth Enterprise Market in August 2021, is a biotechnology company engaged in the research and development, production, sales and provision of technical services of biological reagents, the main business includes products such as recombinant proteins, antibodies, genes and culture media, as well as services such as the development of recombinant proteins and antibodies and bioanalytical testing
.
On the evening of November 23, Yibai Pharmaceutical issued an announcement that the company's anti-tumor drug expansion project was completed and began trial production, and the total investment in fixed assets of the project is expected to be 603 million yuan
.
According to the announcement, the "Meian Science and Technology New City New Factory Construction Project" invested and constructed by Hainan Changan International Pharmaceutical Co.
, Ltd.
, a wholly-owned subsidiary of Yibai Pharmaceutical, has completed the main construction of the project and the installation and commissioning of equipment, and the project has met the conditions for trial production and officially entered the trial production stage
.
Yibai Pharmaceutical said that the commissioning of the project is conducive to improving the company's R&D production efficiency, improving the company's product quality, expanding the company's product scale, further enhancing the company's product market competitiveness, laying a new foundation for the company's future product research and development, pilot and production, and promoting the company's strategic goal
of long-term healthy and sustainable development.
On November 16, Erkang Pharmaceutical also announced that the company will use self-financing of 1 billion yuan to invest in the construction of lithium carbonate and its preparation projects, mainly in Liuyang Economic and Technological Development Zone, and the construction period (including commissioning) is expected to be 6 months
.
Erkang Pharmaceutical is the main construction body
of this lithium carbonate and its preparation project.
Of the RMB1 billion investment arrangement, RMB400 million is construction investment, of which RMB100 million is spent on construction projects, RMB260 million on equipment purchase, RMB40 million on installation projects, and RMB600 million is working capital
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
